{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T04:46:06Z","timestamp":1794458766890,"version":"4.9.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":94,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82000629"],"award-info":[{"award-number":["82000629"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"DOI":"10.1186\/s12951-026-04773-9","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T15:54:20Z","timestamp":1783094060000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Degradable MMP9\u2013responsive high-density lipoprotein nanoparticles enable efficient siRNA-PGRN and quercetin delivery to remodel the fibrotic microenvironment and attenuate renal fibrosis"],"prefix":"10.1186","volume":"24","author":[{"given":"Weichao","family":"Tu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yikun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"4773_CR1","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1093\/ndt\/gfae048","volume":"39","author":"R Duff","year":"2024","unstructured":"Duff R, Awofala O, Arshad MT, et al. Global health inequalities of chronic kidney disease: a meta-analysis. Nephrol Dial Transplant. 2024;39:1692\u2013709. https:\/\/doi.org\/10.1093\/ndt\/gfae048.","journal-title":"Nephrol Dial Transplant"},{"key":"4773_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","volume":"12","author":"CP Kovesdy","year":"2011","unstructured":"Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl. 2011;12:7\u201311. https:\/\/doi.org\/10.1016\/j.kisu.2021.11.003.","journal-title":"Kidney Int Suppl"},{"key":"4773_CR3","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41392-023-01379-7","volume":"8","author":"R Huang","year":"2023","unstructured":"Huang R, Fu P, Ma L. Kidney fibrosis: from mechanisms to therapeutic medicines. Signal Transduct Target Ther. 2023;8:129. https:\/\/doi.org\/10.1038\/s41392-023-01379-7.","journal-title":"Signal Transduct Target Ther"},{"key":"4773_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1553794","volume":"16","author":"X Wang","year":"2025","unstructured":"Wang X, Liang Y, Yang F, et al. Molecular mechanisms and targeted therapy of progranulin in metabolic diseases. Front Endocrinol (Lausanne). 2025;16:1553794. https:\/\/doi.org\/10.3389\/fendo.2025.1553794.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"4773_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-025-05716-7","volume":"82","author":"WC Tu","year":"2025","unstructured":"Tu WC, He YK, Wang DW, et al. Progranulin enhances M2 macrophage polarization and renal fibrosis by modulating autophagy in chronic kidney disease. Cell Mol Life Sci. 2025;82:186. https:\/\/doi.org\/10.1007\/s00018-025-05716-7.","journal-title":"Cell Mol Life Sci"},{"key":"4773_CR6","doi-asserted-by":"publisher","first-page":"174","DOI":"10.23876\/j.krcp.22.159","volume":"42","author":"C Wang","year":"2023","unstructured":"Wang C, Li SW, Zhong X, et al. An update on renal fibrosis: from mechanisms to therapeutic strategies with a focus on extracellular vesicles. Kidney Res Clin Pract. 2023;42:174\u201387. https:\/\/doi.org\/10.23876\/j.krcp.22.159.","journal-title":"Kidney Res Clin Pract"},{"key":"4773_CR7","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1186\/s12951-023-02147-z","volume":"21","author":"SS Ali Zaidi","year":"2023","unstructured":"Ali Zaidi SS, Fatima F, Ali Zaidi SA, et al. Engineering siRNA therapeutics: challenges and strategies. J Nanobiotechnology. 2023;21:381. https:\/\/doi.org\/10.1186\/s12951-023-02147-z.","journal-title":"J Nanobiotechnology"},{"key":"4773_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26083456","author":"O Ebenezer","year":"2025","unstructured":"Ebenezer O, Oyebamiji AK, Olanlokun JO, et al. Recent update on siRNA therapeutics. Int J Mol Sci. 2025. https:\/\/doi.org\/10.3390\/ijms26083456.","journal-title":"Int J Mol Sci"},{"key":"4773_CR9","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1053\/j.ajkd.2021.11.010","volume":"80","author":"M Ruiz-Ortega","year":"2022","unstructured":"Ruiz-Ortega M, Lamas S, Ortiz A. Antifibrotic agents for the management of CKD: a review. Am J Kidney Dis. 2022;80:251\u201363. https:\/\/doi.org\/10.1053\/j.ajkd.2021.11.010.","journal-title":"Am J Kidney Dis"},{"key":"4773_CR10","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1177\/15353702221147569","volume":"248","author":"S Min","year":"2023","unstructured":"Min S, Chang D, Wang YC, et al. Novel small-molecule compound VCP979 attenuates renal fibrosis in male rats with unilateral ureteral obstruction. Exp Biol Med (Maywood). 2023;248:327\u201338. https:\/\/doi.org\/10.1177\/15353702221147569.","journal-title":"Exp Biol Med (Maywood)"},{"key":"4773_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.689044","volume":"12","author":"P Shen","year":"2021","unstructured":"Shen P, Lin W, Deng X, et al. Potential implications of quercetin in autoimmune diseases. Front Immunol. 2021;12:689044. https:\/\/doi.org\/10.3389\/fimmu.2021.689044.","journal-title":"Front Immunol"},{"key":"4773_CR12","doi-asserted-by":"publisher","first-page":"3997190","DOI":"10.1155\/2022\/3997190","volume":"2022","author":"G Wang","year":"2022","unstructured":"Wang G, Wang Y, Yao L, et al. Pharmacological activity of quercetin: an updated review. Evid Based Compl Alternat Med. 2022;2022:3997190. https:\/\/doi.org\/10.1155\/2022\/3997190.","journal-title":"Evid Based Compl Alternat Med"},{"key":"4773_CR13","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.13257","volume":"10","author":"W Widowati","year":"2022","unstructured":"Widowati W, Prahastuti S, Tjokropranoto R, et al. Quercetin prevents chronic kidney disease on mesangial cells model by regulating inflammation, oxidative stress, and TGF-\u03b21\/SMADs pathway. PeerJ. 2022;10:e13257. https:\/\/doi.org\/10.7717\/peerj.13257.","journal-title":"PeerJ"},{"key":"4773_CR14","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2147\/ijn.S116010","volume":"12","author":"MX Xu","year":"2017","unstructured":"Xu MX, Wang M, Yang WW. Gold-quercetin nanoparticles prevent metabolic endotoxemia-induced kidney injury by regulating TLR4\/NF-\u03baB signaling and Nrf2 pathway in high fat diet fed mice. Int J Nanomedicine. 2017;12:327\u201345. https:\/\/doi.org\/10.2147\/ijn.S116010.","journal-title":"Int J Nanomedicine"},{"key":"4773_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15061656","author":"EM Tomou","year":"2023","unstructured":"Tomou EM, Papakyriakopoulou P, Saitani EM, et al. Recent advances in nanoformulations for quercetin delivery. Pharmaceutics. 2023. https:\/\/doi.org\/10.3390\/pharmaceutics15061656.","journal-title":"Pharmaceutics"},{"key":"4773_CR16","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","volume":"20","author":"MJ Mitchell","year":"2021","unstructured":"Mitchell MJ, Billingsley MM, Haley RM, et al. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20:101\u201324. https:\/\/doi.org\/10.1038\/s41573-020-0090-8.","journal-title":"Nat Rev Drug Discov"},{"key":"4773_CR17","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1039\/d0tb02139c","volume":"9","author":"Y Mei","year":"2021","unstructured":"Mei Y, Tang L, Xiao Q, et al. Reconstituted high density lipoprotein (rHDL), a versatile drug delivery nanoplatform for tumor targeted therapy. J Mater Chem B. 2021;9:612\u201333. https:\/\/doi.org\/10.1039\/d0tb02139c.","journal-title":"J Mater Chem B"},{"key":"4773_CR18","doi-asserted-by":"publisher","first-page":"35248","DOI":"10.1021\/acsami.1c02074","volume":"13","author":"C Jiang","year":"2021","unstructured":"Jiang C, Wang X, Teng B, et al. Peptide-targeted high-density lipoprotein nanoparticles for combinatorial treatment against metastatic breast cancer. ACS Appl Mater Interfaces. 2021;13:35248\u201365. https:\/\/doi.org\/10.1021\/acsami.1c02074.","journal-title":"ACS Appl Mater Interfaces"},{"key":"4773_CR19","doi-asserted-by":"publisher","DOI":"10.1080\/0886022x.2025.2499897","volume":"47","author":"D Shen","year":"2025","unstructured":"Shen D, Lin L, Su Y, et al. Inhibition of matrix metalloproteinase-9 attenuates kidney fibrosis and cellular senescence in the transition from acute kidney injury to chronic kidney disease. Ren Fail. 2025;47:2499897. https:\/\/doi.org\/10.1080\/0886022x.2025.2499897.","journal-title":"Ren Fail"},{"key":"4773_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/ph16071020","author":"F Aghababaei","year":"2023","unstructured":"Aghababaei F, Hadidi M. Recent advances in potential health benefits of quercetin. Pharmaceuticals (Basel). 2023. https:\/\/doi.org\/10.3390\/ph16071020.","journal-title":"Pharmaceuticals (Basel)"},{"key":"4773_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/genes16080856","author":"VR V\u00e1squez-Garz\u00f3n","year":"2025","unstructured":"V\u00e1squez-Garz\u00f3n VR, Vel\u00e1zquez-Enr\u00edquez JM, Santos-\u00c1lvarez JC, et al. Quercetin in idiopathic pulmonary fibrosis and its comorbidities: gene regulatory mechanisms and therapeutic implications. Genes (Basel). 2025. https:\/\/doi.org\/10.3390\/genes16080856.","journal-title":"Genes (Basel)"},{"key":"4773_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.968226","volume":"13","author":"YQ Chen","year":"2022","unstructured":"Chen YQ, Chen HY, Tang QQ, et al. Protective effect of quercetin on kidney diseases: from chemistry to herbal medicines. Front Pharmacol. 2022;13:968226. https:\/\/doi.org\/10.3389\/fphar.2022.968226.","journal-title":"Front Pharmacol"},{"key":"4773_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-05781-9","volume":"15","author":"A Banerjee","year":"2025","unstructured":"Banerjee A, Das D, Manna K, et al. An intricate role of Ang II\/AT1 in the modulation of monosodium glutamate-induced pulmonary fibrosis by TGF-\u03b2\/Smad through quercetin. Sci Rep. 2025;15:21112. https:\/\/doi.org\/10.1038\/s41598-025-05781-9.","journal-title":"Sci Rep"},{"key":"4773_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1594757","volume":"16","author":"Y Lan","year":"2025","unstructured":"Lan Y, Dong C, Wu M, et al. Quercetin ameliorates epithelial-mesenchymal transition and inflammation by targeting FSTL1 and modulating the NF-\u03baB pathway in pulmonary fibrosis. Front Pharmacol. 2025;16:1594757. https:\/\/doi.org\/10.3389\/fphar.2025.1594757.","journal-title":"Front Pharmacol"},{"key":"4773_CR25","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/ptr.7599","volume":"37","author":"Q Wang","year":"2023","unstructured":"Wang Q, Wang F, Li X, et al. Quercetin inhibits the amphiregulin\/EGFR signaling-mediated renal tubular epithelial-mesenchymal transition and renal fibrosis in obstructive nephropathy. Phytother Res. 2023;37:111\u201323. https:\/\/doi.org\/10.1002\/ptr.7599.","journal-title":"Phytother Res"},{"key":"4773_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1660599","volume":"16","author":"H Liu","year":"2025","unstructured":"Liu H, Yang Q, Wang S, et al. Quercetin ameliorates renal injury in hyperuricemic rats via modulating ER stress pathways. Front Pharmacol. 2025;16:1660599. https:\/\/doi.org\/10.3389\/fphar.2025.1660599.","journal-title":"Front Pharmacol"},{"key":"4773_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11112238","author":"HY Chen","year":"2022","unstructured":"Chen HY, Chiang YF, Hong YH, et al. Quercetin ameliorates renal injury and pyroptosis in lupus nephritis through inhibiting IL-33\/ST2 pathway in vitro and in vivo. Antioxidants (Basel). 2022. https:\/\/doi.org\/10.3390\/antiox11112238.","journal-title":"Antioxidants (Basel)"},{"key":"4773_CR28","doi-asserted-by":"publisher","first-page":"6538","DOI":"10.1080\/21655979.2021.1973877","volume":"12","author":"H Tu","year":"2021","unstructured":"Tu H, Ma D, Luo Y, et al. Quercetin alleviates chronic renal failure by targeting the PI3k\/Akt pathway. Bioengineered. 2021;12:6538\u201358. https:\/\/doi.org\/10.1080\/21655979.2021.1973877.","journal-title":"Bioengineered"},{"key":"4773_CR29","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1142\/s0192415x25500715","volume":"53","author":"XL Gao","year":"2025","unstructured":"Gao XL, Chen T, Lin SL, et al. Quercetin alleviates folic acid-induced renal fibrosis by inhibiting tubular epithelial cell ferroptosis via EGFR\/ACSL4 pathway. Am J Chin Med. 2025;53:1913\u201331. https:\/\/doi.org\/10.1142\/s0192415x25500715.","journal-title":"Am J Chin Med"},{"key":"4773_CR30","doi-asserted-by":"publisher","DOI":"10.1097\/imna-d-24-00051","volume":"12","author":"W Wang","year":"2025","unstructured":"Wang W, Wu W. Therapeutic effects of quercetin on renal fibrosis and injury. Integr Med Nephrol Androl. 2025;12:e24-00051. https:\/\/doi.org\/10.1097\/imna-d-24-00051.","journal-title":"Integr Med Nephrol Androl"},{"key":"4773_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2025.104997","volume":"414","author":"A Abudoureyimu","year":"2025","unstructured":"Abudoureyimu A, Chen C, Hu Y, et al. Quercetin alleviates diabetic nephropathy by inhibiting M1 macrophage polarization via targeting NLRC5\/NLRP3 pathway. Cell Immunol. 2025;414:104997. https:\/\/doi.org\/10.1016\/j.cellimm.2025.104997.","journal-title":"Cell Immunol"},{"key":"4773_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.912029","volume":"13","author":"F Geng","year":"2022","unstructured":"Geng F, Xu M, Zhao L, et al. Quercetin alleviates pulmonary fibrosis in mice exposed to silica by inhibiting macrophage senescence. Front Pharmacol. 2022;13:912029. https:\/\/doi.org\/10.3389\/fphar.2022.912029.","journal-title":"Front Pharmacol"},{"key":"4773_CR33","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.3390\/cimb45040202","volume":"45","author":"F Geng","year":"2023","unstructured":"Geng F, Zhao L, Cai Y, et al. Quercetin alleviates pulmonary fibrosis in silicotic mice by inhibiting macrophage transition and TGF-\u03b2-Smad2\/3 pathway. Curr Issues Mol Biol. 2023;45:3087\u2013101. https:\/\/doi.org\/10.3390\/cimb45040202.","journal-title":"Curr Issues Mol Biol"},{"key":"4773_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56223-z","volume":"16","author":"S He","year":"2025","unstructured":"He S, Li X, He Y, et al. High-density lipoprotein nanoparticles spontaneously target to damaged renal tubules and alleviate renal fibrosis by remodeling the fibrotic niches. Nat Commun. 2025;16:1061. https:\/\/doi.org\/10.1038\/s41467-025-56223-z.","journal-title":"Nat Commun"},{"key":"4773_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15051504","author":"A Rani","year":"2023","unstructured":"Rani A, Marsche G. A Current update on the role of HDL-based nanomedicine in targeting macrophages in cardiovascular disease. Pharmaceutics. 2023. https:\/\/doi.org\/10.3390\/pharmaceutics15051504.","journal-title":"Pharmaceutics"},{"key":"4773_CR36","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s12951-024-02529-x","volume":"22","author":"J Zhen","year":"2024","unstructured":"Zhen J, Li X, Yu H, et al. High-density lipoprotein mimetic nano-therapeutics targeting monocytes and macrophages for improved cardiovascular care: a comprehensive review. J Nanobiotechnol. 2024;22:263. https:\/\/doi.org\/10.1186\/s12951-024-02529-x.","journal-title":"J Nanobiotechnol"},{"key":"4773_CR37","doi-asserted-by":"publisher","DOI":"10.31083\/j.fbl2905192","volume":"29","author":"A La Russa","year":"2024","unstructured":"La Russa A, Serra R, Faga T, et al. Kidney fibrosis and matrix metalloproteinases (MMPs). Front Biosci (Landmark Ed). 2024;29:192. https:\/\/doi.org\/10.31083\/j.fbl2905192.","journal-title":"Front Biosci (Landmark Ed)"},{"key":"4773_CR38","doi-asserted-by":"publisher","first-page":"F967","DOI":"10.1152\/ajprenal.00179.2024","volume":"327","author":"RJ Tan","year":"2024","unstructured":"Tan RJ, Liu Y. Matrix metalloproteinases in kidney homeostasis and diseases: an update. Am J Physiol Renal Physiol. 2024;327:F967\u201384. https:\/\/doi.org\/10.1152\/ajprenal.00179.2024.","journal-title":"Am J Physiol Renal Physiol"},{"key":"4773_CR39","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1080\/17425247.2021.1828339","volume":"18","author":"J Majumder","year":"2021","unstructured":"Majumder J, Minko T. Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery. Expert Opin Drug Deliv. 2021;18:205\u201327. https:\/\/doi.org\/10.1080\/17425247.2021.1828339.","journal-title":"Expert Opin Drug Deliv"},{"key":"4773_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2021.707319","volume":"9","author":"D Chang","year":"2021","unstructured":"Chang D, Ma Y, Xu X, et al. Stimuli-responsive polymeric nanoplatforms for cancer therapy. Front Bioeng Biotechnol. 2021;9:707319. https:\/\/doi.org\/10.3389\/fbioe.2021.707319.","journal-title":"Front Bioeng Biotechnol"},{"key":"4773_CR41","doi-asserted-by":"publisher","first-page":"16488","DOI":"10.1039\/d3ra00866e","volume":"13","author":"T Wang","year":"2023","unstructured":"Wang T, Wu C, Hu Y, et al. Stimuli-responsive nanocarrier delivery systems for Pt-based antitumor complexes: a review. RSC Adv. 2023;13:16488\u2013511. https:\/\/doi.org\/10.1039\/d3ra00866e.","journal-title":"RSC Adv"},{"key":"4773_CR42","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1016\/j.apsb.2024.04.026","volume":"14","author":"F Yang","year":"2024","unstructured":"Yang F, Cheng MH, Pan HF, et al. Progranulin: a promising biomarker and therapeutic target for fibrotic diseases. Acta Pharm Sin B. 2024;14:3312\u201326. https:\/\/doi.org\/10.1016\/j.apsb.2024.04.026.","journal-title":"Acta Pharm Sin B"},{"key":"4773_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.crphys.2024.100133","volume":"8","author":"SK Masenga","year":"2025","unstructured":"Masenga SK, Desta S, Hatcher M, et al. How PPAR-alpha mediated inflammation may affect the pathophysiology of chronic kidney disease. Curr Res Physiol. 2025;8:100133. https:\/\/doi.org\/10.1016\/j.crphys.2024.100133.","journal-title":"Curr Res Physiol"},{"key":"4773_CR44","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1538\/expanim.23-0080","volume":"73","author":"E Adachi","year":"2024","unstructured":"Adachi E, Murakoshi M, Shibata T, et al. Progranulin deficiency attenuates tubulointerstitial injury in a mouse unilateral ureteral obstruction model. Exp Anim. 2024;73:293\u2013301. https:\/\/doi.org\/10.1538\/expanim.23-0080.","journal-title":"Exp Anim"},{"key":"4773_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25084467","author":"M V\u00e1zquez-Carrera","year":"2024","unstructured":"V\u00e1zquez-Carrera M, Wahli W. PPARs as key transcription regulators at the crossroads of metabolism and inflammation. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25084467.","journal-title":"Int J Mol Sci"},{"key":"4773_CR46","doi-asserted-by":"publisher","first-page":"F208","DOI":"10.1152\/ajprenal.00046.2024","volume":"327","author":"Y Katsuma","year":"2024","unstructured":"Katsuma Y, Matsui I, Matsumoto A, et al. Endogenous activation of peroxisome proliferator-activated receptor-\u03b1 in proximal tubule cells in counteracting phosphate toxicity. Am J Physiol Renal Physiol. 2024;327:F208\u201323. https:\/\/doi.org\/10.1152\/ajprenal.00046.2024.","journal-title":"Am J Physiol Renal Physiol"},{"key":"4773_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-74340-5","volume":"14","author":"Y Shinkai","year":"2024","unstructured":"Shinkai Y, Sasaki K, Tamura R, et al. Selective activation of PPAR\u03b1 by pemafibrate mitigates peritoneal inflammation and fibrosis through suppression of NLRP3 inflammasome and modulation of inflammation. Sci Rep. 2024;14:23816. https:\/\/doi.org\/10.1038\/s41598-024-74340-5.","journal-title":"Sci Rep"},{"key":"4773_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.121590","volume":"321","author":"Y Horinouchi","year":"2023","unstructured":"Horinouchi Y, Murashima Y, Yamada Y, et al. Pemafibrate inhibited renal dysfunction and fibrosis in a mouse model of adenine-induced chronic kidney disease. Life Sci. 2023;321:121590. https:\/\/doi.org\/10.1016\/j.lfs.2023.121590.","journal-title":"Life Sci"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-026-04773-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04773-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04773-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:28:28Z","timestamp":1791160108000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12951-026-04773-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4773"],"URL":"https:\/\/doi.org\/10.1186\/s12951-026-04773-9","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"27 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study has been approved by the Animal Ethics Committee of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine (Approval No.: RJ2024033).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"923"}}